New allergen patterns in beer allergy

Experience shows that people who have an allergic reaction to beer are merely greeted with a grin from those around them. Nevertheless, these reactions can definitely be life-threatening. The prevalence of beer allergy in Germany is low. Therefore cooperation with Chongquing Medical University (China) and a CK-CARE exchange programme provided a useful opportunity to study 20 cases of anaphylaxis following beer consumption.

As well as detailed history-taking and clinical examination, skin tests were performed with 12 different materials. These originated from native beer production in collaboration with the Institute of Brewing and Beverage Technology at the Weihenstephan Science Centre of the Technical University of Munich (TUM) and comprised not only barley and barley malt but also sorghum, millet, maize and yeast, hops and enzymes, substances which are used in China but also in many countries around the world. Furthermore, various original types of beer were introduced into the tests. In addition, oral challenge tests were performed after the success of the skin testing.

75% of the patients showed positive reactions to at least one or more beer ingredients, most commonly to sorghum and sorghum malt. Seventeen patients reacted in the oral challenge with predominantly skin symptoms in the form of flush and urticaria, which lasted up to two hours. A total of 5 patients reacted to hops, 2 of them reacting solely to hops. Seven patients reacted to millet but frequently in concurrent reactions to barley or sorghum. One patient reacted to yeast in isolation. It may be concluded from these tests that beer allergy is not a simple phenomenon, but quite different ingredients in beer can trigger severe reactions. In conjunction with growing globalisation and the availability of foreign beer varieties, an increase in beer allergies might also be observed in Central Europe (Song et al 2013 in press). To pre-empt possible comments, we have also observed cases of anaphylactic reactions to grape juice and wine.

20th CK-CARE Team Meeting 2025

The 20th CK-CARE Team Meeting took place on 24 and 25 February 2025 under the motto ‘Embracing the concept of data analysis to further personalised patient care’. The aim of the meeting was to develop innovative ideas and prepare a draft publication for the CK-CARE Scientific Board based on the data from the CK-CARE registry and biobank. The event began with an informative presentation of the data from the CK-CARE repository and the biobank, which provided the framework for intensive group work. The participants were divided into four teams: Team 1, 2 and 3 chose the topic according to their personal interest based on the available data from the CKC repository and the biobank, while team 4 focused on science communication for the NIA app. The day was rounded off with a guided tour of the historic Fuggerei in Augsburg followed by a tapas dinner at the Tafeldecker restaurant, which provided space for lively discussions. On Tuesday, each group presented their idea in a 3-minute ‘Scientific Paper Pitch’ to the critical members of the ‘CK-CARE Scientific Board-lion’s den’.

(Copyright Image: Samuel Tschaffon, UK Augsburg)

Global Allergy Forum 2022

The 4th Davos Declaration: A Milestone for Atopic Dermatitis Patient Care

During the last Global Allergy Forum (GAF) key opinion leaders from science, medicine and industry met in Davos to discuss the current state of the art of patient care in atopic dermatitis (AD) and proposed new strategies for its improvement. The thinktank addressed the high prevalence of AD and strategized methods to advance research, diagnostics, management and prevention. The findings are now published as «Navigating the Evolving Landscape of Atopic Dermatitis: Challenges and Future Opportunities: the 4th Davos Declaration».

Annual Report CK-CARE 2023

CK-CARE’s work has global resonance and, thanks to this strong position, significant projects in clinical allergy research were again launched or catalysed in the reporting year. CK-CARE’s working methods were sharpened in terms of medical translation and a strengthening of research capacities on the medical campus in Davos was defined in order to increase CK-CARE’s performance.

Annual Report 2023

CK-CARE’s work now has global resonance and, thanks to this strong position, significant projects in clinical allergy research were again launched or catalysed in the reporting year. CK-CARE’s working methods were sharpened in terms of medical translation and a strengthening of research capacities on the medical campus in Davos was defined in order to increase CK-CARE’s performance.

Kühne-Foundation Annual Report 2023

“Entrepreneurial success should go hand in hand with the promotion of  the common good. The Kühne Foundation fulfills this task. With a variety of programs and projects, the founder and the Kühne Foundation also assume their socio-political responsibility.”

The activities were significantly expanded, particularly in the area of logistics. In addition, the new focus area of climate action was established, and the first projects were launched.

Prof. Dr. h.c. Klaus-Michael Kühne

 

How flexible are neutrophils to opposing signaling?

Paola Martinez Murillo a postdoctoral researcher in Pierre-Yves Mantel’s group from CK-CARE obtained a Spark grant from the SNSF to investigate the effect of opposite signals on neutrophil biology in atopic dermatitis.

Spark is a Swiss National Science Foundation (SNSF) funding scheme aiming to support projects that show unconventional thinking and introduce a unique approach. The Spark is highly competitive and supports projects based on promising ideas of high originality. CK-CARE was recognized as an eligible institution in June 2023 by the SNSF, opening new funding opportunities for the CK-CARE researchers.

This project aims to understand how two opposing signals: eczema dysregulated immune environment (Th2 response) and bacterial colonization (Th1 response) impact neutrophils function.

Neutrophils are tiny but powerful immune cells in our blood that fight off bacteria and viruses. They live for only 2-3 days and can quickly respond to infections. Neutrophils can adapt to different situations thanks to their genetic instructions (RNA). Our body’s reversible changes in reading DNA, called epigenomic modifications, are crucial for a functional immune response.

Eczema, a chronic skin condition, happens when various factors like genetics, skin damage, and immune reactions go haywire. People with eczema have neutrophils that do not work as well in fighting bacteria, making them more prone to infections.

This study addresses a knowledge gap in neutrophil adaptation to an allergic milieu, by evaluating neutrophil adaptation to anti-bacterial response in a type 2 immune response dominated context such as atopic dermatitis using transcriptional and epigenomic profiling along with comprehensive analysis of neutrophil functionality (netosis, phagocytosis, ROS-production, bactericidal activity, chemotaxis). Building upon in-vitro stimulation insights, then we will aim for a comprehensive analysis of neutrophil functionality in atopic dermatitis patients treated or not with Dupilumab.